Yali Chai , Qingrong Xia , Jian Cheng , Junwei Yan , Chao Li , Xiaoming Kong , Jiayi Hu , Jianliang Gao , Loufeng Zhang , Peijun Ju , Cuizhen Zhu
{"title":"白细胞介素-18在连接代谢和精神症状中的双重作用:来自精神分裂症机器学习的见解","authors":"Yali Chai , Qingrong Xia , Jian Cheng , Junwei Yan , Chao Li , Xiaoming Kong , Jiayi Hu , Jianliang Gao , Loufeng Zhang , Peijun Ju , Cuizhen Zhu","doi":"10.1016/j.pnpbp.2025.111473","DOIUrl":null,"url":null,"abstract":"<div><div>Interleukin-18 (IL-18) has been implicated in both metabolic syndrome (MetS) and schizophrenia, but its dual role in their comorbidity remains unclear. This study aimed to explore how IL-18 interacts with metabolic and psychiatric aspects in this context. We recruited 146 participants divided into three groups: MetS (<em>n</em> = 48), non-MetS (<em>n</em> = 54), and healthy controls (<em>n</em> = 44). Psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale, while biochemical parameters were measured via an automatic biochemistry analyzer. Levels of 14 cytokines/chemokines, including IL-4, IL-8, IL-10, IL-13, IL-18, and Eotaxin were detected using Meso Scale Discovery (MSD) technology. Linear regression and Gradient Boosting Machine (GBM) models revealed that IL-18 significantly impacted metabolic indices (e.g., triglycerides, waist circumference, BMI) and psychiatric symptoms (e.g., psychopathology score, aggressiveness score, PANSS total score) in the MetS group. Analysis using Partial Dependence Plots (PDP) and Accumulated Local Effects (ALE) plots revealed that IL-18 had complex, non-linear interactions with metabolic markers and clinical symptoms. To further elucidate the comprehensive effects of IL-18 on metabolism and symptoms, we integrated these markers into two overarching domains: metabolic and symptomatic. Extreme Gradient Boosting (XGBoost) regression models and SHapley Additive exPlanations (SHAP) values were then employed to quantify the influence of IL-18 on these domains. Results indicated that IL-18's impact on clinical symptoms was more pronounced at lower levels, diminishing as its concentration increased, while its metabolic impact was more significant at higher levels. This study highlights IL-18's dual role as an inflammatory bridge between metabolic dysregulation and psychopathology in comorbidity and underscores the need for further investigation into the underlying mechanisms driving these non-linear interactions.</div></div>","PeriodicalId":54549,"journal":{"name":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","volume":"141 ","pages":"Article 111473"},"PeriodicalIF":3.9000,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dual role of Interleukin-18 in linking metabolic and psychiatric symptoms: Insights from machine learning in schizophrenia\",\"authors\":\"Yali Chai , Qingrong Xia , Jian Cheng , Junwei Yan , Chao Li , Xiaoming Kong , Jiayi Hu , Jianliang Gao , Loufeng Zhang , Peijun Ju , Cuizhen Zhu\",\"doi\":\"10.1016/j.pnpbp.2025.111473\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Interleukin-18 (IL-18) has been implicated in both metabolic syndrome (MetS) and schizophrenia, but its dual role in their comorbidity remains unclear. This study aimed to explore how IL-18 interacts with metabolic and psychiatric aspects in this context. We recruited 146 participants divided into three groups: MetS (<em>n</em> = 48), non-MetS (<em>n</em> = 54), and healthy controls (<em>n</em> = 44). Psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale, while biochemical parameters were measured via an automatic biochemistry analyzer. Levels of 14 cytokines/chemokines, including IL-4, IL-8, IL-10, IL-13, IL-18, and Eotaxin were detected using Meso Scale Discovery (MSD) technology. Linear regression and Gradient Boosting Machine (GBM) models revealed that IL-18 significantly impacted metabolic indices (e.g., triglycerides, waist circumference, BMI) and psychiatric symptoms (e.g., psychopathology score, aggressiveness score, PANSS total score) in the MetS group. Analysis using Partial Dependence Plots (PDP) and Accumulated Local Effects (ALE) plots revealed that IL-18 had complex, non-linear interactions with metabolic markers and clinical symptoms. To further elucidate the comprehensive effects of IL-18 on metabolism and symptoms, we integrated these markers into two overarching domains: metabolic and symptomatic. Extreme Gradient Boosting (XGBoost) regression models and SHapley Additive exPlanations (SHAP) values were then employed to quantify the influence of IL-18 on these domains. Results indicated that IL-18's impact on clinical symptoms was more pronounced at lower levels, diminishing as its concentration increased, while its metabolic impact was more significant at higher levels. This study highlights IL-18's dual role as an inflammatory bridge between metabolic dysregulation and psychopathology in comorbidity and underscores the need for further investigation into the underlying mechanisms driving these non-linear interactions.</div></div>\",\"PeriodicalId\":54549,\"journal\":{\"name\":\"Progress in Neuro-Psychopharmacology & Biological Psychiatry\",\"volume\":\"141 \",\"pages\":\"Article 111473\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-08-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Progress in Neuro-Psychopharmacology & Biological Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0278584625002271\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Progress in Neuro-Psychopharmacology & Biological Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0278584625002271","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Dual role of Interleukin-18 in linking metabolic and psychiatric symptoms: Insights from machine learning in schizophrenia
Interleukin-18 (IL-18) has been implicated in both metabolic syndrome (MetS) and schizophrenia, but its dual role in their comorbidity remains unclear. This study aimed to explore how IL-18 interacts with metabolic and psychiatric aspects in this context. We recruited 146 participants divided into three groups: MetS (n = 48), non-MetS (n = 54), and healthy controls (n = 44). Psychiatric symptoms were assessed using the Positive and Negative Syndrome Scale, while biochemical parameters were measured via an automatic biochemistry analyzer. Levels of 14 cytokines/chemokines, including IL-4, IL-8, IL-10, IL-13, IL-18, and Eotaxin were detected using Meso Scale Discovery (MSD) technology. Linear regression and Gradient Boosting Machine (GBM) models revealed that IL-18 significantly impacted metabolic indices (e.g., triglycerides, waist circumference, BMI) and psychiatric symptoms (e.g., psychopathology score, aggressiveness score, PANSS total score) in the MetS group. Analysis using Partial Dependence Plots (PDP) and Accumulated Local Effects (ALE) plots revealed that IL-18 had complex, non-linear interactions with metabolic markers and clinical symptoms. To further elucidate the comprehensive effects of IL-18 on metabolism and symptoms, we integrated these markers into two overarching domains: metabolic and symptomatic. Extreme Gradient Boosting (XGBoost) regression models and SHapley Additive exPlanations (SHAP) values were then employed to quantify the influence of IL-18 on these domains. Results indicated that IL-18's impact on clinical symptoms was more pronounced at lower levels, diminishing as its concentration increased, while its metabolic impact was more significant at higher levels. This study highlights IL-18's dual role as an inflammatory bridge between metabolic dysregulation and psychopathology in comorbidity and underscores the need for further investigation into the underlying mechanisms driving these non-linear interactions.
期刊介绍:
Progress in Neuro-Psychopharmacology & Biological Psychiatry is an international and multidisciplinary journal which aims to ensure the rapid publication of authoritative reviews and research papers dealing with experimental and clinical aspects of neuro-psychopharmacology and biological psychiatry. Issues of the journal are regularly devoted wholly in or in part to a topical subject.
Progress in Neuro-Psychopharmacology & Biological Psychiatry does not publish work on the actions of biological extracts unless the pharmacological active molecular substrate and/or specific receptor binding properties of the extract compounds are elucidated.